Key result
Pioglitazone, heat shock protein induction, and antioxidants reduce atrial fibrosis and AF vulnerability in rats.
Why the study?
Do pioglitazone, heat shock protein induction, and antioxidant agents prevent atrial fibrosis in experimental models of atrial fibrillation?
Do pioglitazone, heat shock protein induction, and antioxidant agents prevent atrial fibrosis in experimental models of atrial fibrillation?
Inflammatory profibrotic processes are essential for atrial fibrosis development, and targeting these pathways with pioglitazone, HSP induction, or antioxidants may represent novel therapeutic approaches to prevent atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Should not change practice; leaves open translation of antifibrotic effects to human AF.
Takahashi et al. (2012) conducted a review in Atrial fibrosis and atrial fibrillation. Pioglitazone, heat shock protein induction, and antioxidant agents vs. Vehicle or sham was evaluated on Atrial fibrosis and AF vulnerability. Pioglitazone, induction of heat shock proteins, and antioxidant agents attenuated atrial fibrosis and reduced vulnerability to atrial fibrillation in experimental rat models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: